396 related articles for article (PubMed ID: 27889832)
1. Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials.
Dymond AW; So K; Martin P; Huang Y; Severin P; Mathews D; Lisbon E; Mariani G
Eur J Clin Pharmacol; 2017 Feb; 73(2):175-184. PubMed ID: 27889832
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from 10 phase I trials.
Patel P; Howgate E; Martin P; Carlile DJ; Aarons L; Zhou D
Br J Clin Pharmacol; 2018 Jan; 84(1):52-63. PubMed ID: 28833380
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole.
Martin P; Oliver S; Robertson J; Kennedy SJ; Read J; Duvauchelle T
Drugs R D; 2011; 11(1):37-51. PubMed ID: 21410294
[TBL] [Abstract][Full Text] [Related]
4. Open-Label Assessment of the Effects of Itraconazole and Rifampicin on Balovaptan Pharmacokinetics in Healthy Volunteers.
Derks MGM; Wandel C; Young A; Bolt SK; Meyenberg C
Adv Ther; 2020 Nov; 37(11):4720-4729. PubMed ID: 32935287
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs.
Nomoto M; Zamora CA; Schuck E; Boyd P; Chang MK; Aluri J; Siu YA; Lai WG; Yasuda S; Ferry J; Rege B
Br J Clin Pharmacol; 2018 May; 84(5):952-960. PubMed ID: 29341245
[TBL] [Abstract][Full Text] [Related]
6. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.
Fukumura K; Kawaguchi N; Ishibashi T; Kubota R; Tada Y; Ogura E
Clin Drug Investig; 2020 Jun; 40(6):529-540. PubMed ID: 32323104
[TBL] [Abstract][Full Text] [Related]
7. Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies.
Dirix L; Swaisland H; Verheul HM; Rottey S; Leunen K; Jerusalem G; Rolfo C; Nielsen D; Molife LR; Kristeleit R; Vos-Geelen J; Mau-Sørensen M; Soetekouw P; van Herpen C; Fielding A; So K; Bannister W; Plummer R
Clin Ther; 2016 Oct; 38(10):2286-2299. PubMed ID: 27745744
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
[TBL] [Abstract][Full Text] [Related]
9. Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study.
Poggesi I; Li LY; Jiao J; Hellemans P; Rasschaert F; de Zwart L; Snoeys J; De Meulder M; Mamidi RNVS; Ouellet D
Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):101-111. PubMed ID: 31673875
[TBL] [Abstract][Full Text] [Related]
10. Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations.
Karonen T; Laitila J; Niemi M; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2012 May; 68(5):681-8. PubMed ID: 22108774
[TBL] [Abstract][Full Text] [Related]
11. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
Li J; Rockich K; Yuska B; Zhou G; Epstein N; Punwani N; Chen X; Yeleswaram S
J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
[TBL] [Abstract][Full Text] [Related]
12. Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens.
Cohen-Rabbie S; Zhou L; Vishwanathan K; Wild M; Xu S; Freshwater T; Jain L; Schalkwijk S; Tomkinson H; Zhou D
J Clin Pharmacol; 2021 Nov; 61(11):1493-1504. PubMed ID: 34196005
[TBL] [Abstract][Full Text] [Related]
13. Effect of High-Dose Esomeprazole on CYP1A2, CYP2C19, and CYP3A4 Activities in Humans: Evidence for Substantial and Long-lasting Inhibition of CYP2C19.
Kaartinen TJK; Tornio A; Tapaninen T; Launiainen T; Isoherranen N; Niemi M; Backman JT
Clin Pharmacol Ther; 2020 Dec; 108(6):1254-1264. PubMed ID: 32558923
[TBL] [Abstract][Full Text] [Related]
14. Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects.
Malhotra B; Dickins M; Alvey C; Jumadilova Z; Li X; Duczynski G; Gandelman K
Br J Clin Pharmacol; 2011 Aug; 72(2):263-9. PubMed ID: 21545485
[TBL] [Abstract][Full Text] [Related]
15. The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator.
Elgart A; Greenblatt DJ; Loupe PS; Zur AA; Weiss S; Mimrod D; Spiegelstein O
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):1015-1024. PubMed ID: 32237115
[TBL] [Abstract][Full Text] [Related]
16. Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor.
Desch M; Wunderlich G; Goettel M; Goetz S; Liesenfeld KH; Chan TS; Rosenbrock H; Sennewald R; Link J; Keller S; Wind S
Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):91-103. PubMed ID: 34716565
[TBL] [Abstract][Full Text] [Related]
17. Effect of a strong CYP3A4 inhibitor and inducer on the pharmacokinetics of senaparib (IMP4297) in healthy volunteers: A drug-drug interaction study.
Hu X; Hsieh CY; Zhang Y; Liu W; Xu S; Cai SX; Liu L; Zhang M; Shi H; Zhang H; Liu P; Li X; Xu P
Br J Clin Pharmacol; 2023 Jun; 89(6):1767-1779. PubMed ID: 36458825
[TBL] [Abstract][Full Text] [Related]
18. An Adaptive Physiologically Based Pharmacokinetic-Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers.
Riddell K; Patel A; Collins G; Zhou Y; Schramek D; Kremer BE; Ferron-Brady G
J Clin Pharmacol; 2021 Jan; 61(1):125-137. PubMed ID: 32820548
[TBL] [Abstract][Full Text] [Related]
19. A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib.
Malhi V; Colburn D; Williams SJ; Hop CE; Dresser MJ; Chandra P; Graham RA
Cancer Chemother Pharmacol; 2016 Jul; 78(1):41-9. PubMed ID: 27154174
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healthy Chinese subjects.
Cao B; Huang L; Liu M; Lin H; Ma T; Zhao Y; Geng Y; Yang Y; Guo H; Li J
Expert Opin Drug Metab Toxicol; 2023 Sep; 19(9):653-664. PubMed ID: 37811634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
